BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - BOERSE MUENCHEN 20:45:10 31/05/2024 BST | ||
| 1,171 EUR | -0.17% |
|
| 1 month | +6.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1,171 | -0.17% |
| 30/05/24 | 1,173 | +0.78% |
| 29/05/24 | 1,164 | +0.55% |
| 28/05/24 | 1,158 | -0.75% |
| 27/05/24 | 1,166 | +0.84% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 08:45 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3TA2 |
| ISIN | DE000HD3TA24 |
| Date issued | 18/03/2024 |
| Strike | 1,250 $ |
| Maturity | 20/09/2024 (110 Days) |
| Parity | 1 : 1 |
| Emission price | 1,001 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,182 € |
|---|---|
| Lowest since issue | 930.4 € |
| Spread | 0.14 € |
| Spread % | 0.01% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
